{"id":6011,"date":"2023-08-10T06:30:00","date_gmt":"2023-08-10T06:30:00","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/magnus-ohman-appointed-adjunct-board-member-to-realheart\/"},"modified":"2023-08-10T06:30:00","modified_gmt":"2023-08-10T06:30:00","slug":"magnus-ohman-appointed-adjunct-board-member-to-realheart","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/magnus-ohman-appointed-adjunct-board-member-to-realheart\/","title":{"rendered":"Magnus \u00d6hman Appointed Adjunct Board Member to Realheart"},"content":{"rendered":"
Press Release August 10, 2023<\/p>\n

The nomination committee in Scandinavian Real Heart AB proposes that Magnus \u00d6hman is elected to the board at the next general meeting. Until then, he will be an adjunct to the board. Magnus \u00d6hman has extensive experience from the medical technology industry, including as CEO of St. Jude Medical's Swedish subsidiary within Cardiac Rhythm Management.<\/strong><\/div>\n

The Swedish subsidiary in Cardiac Rhythm Management (CRM) had at the end of Magnus \u00d6hman's time as CEO over 620 employees, of which 200 in research and development, and sales of over SEK 5 billion, of which SEK 900 million from own production. CRM includes products such as pacemakers and defibrillators.<\/span><\/span><\/p>\n

Magnus \u00d6hman currently runs his own consultancy business in leadership and life science and is also chairman of the medical technology company Neosense Technologies AB, focused on reducing mortality and permanent injuries in premature babies. In addition to several roles at St Jude, Magnus \u00d6hman has also been CEO and board member of the Stockholm Technical Institute Foundation, and a mentor in leadership programs.<\/span><\/span><\/p>\n

– "We look forward to welcoming Magnus \u00d6hman to the Board of Directors and taking advantage of his broad expertise, not least on how to build successful growth companies in advanced medical technology for heart disease", says Chairman of the Board Christer Norstr\u00f6m.<\/span><\/span><\/p>\n

\n

For more information please contact:<\/span><\/span><\/strong><\/span><\/p>\n

Ina Laura Perkins, CEO<\/span><\/span><\/p>\n

Phone: +46(0)70 406 49 21\u00a0<\/span><\/span><\/p>\n

E-mail: inalaura.perkins@realheart.se<\/span><\/span><\/p>\n

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se<\/a><\/p>\n<\/div>\n

\n

Scandinavian Real Heart AB utvecklar ett komplett artificiellt hj\u00e4rta (Total Artificial Heart \u2013 TAH) f\u00f6r implantation i patienter med livshotande hj\u00e4rtsvikt. Bolagets TAH har en patenterad design som innefattar en kopiering av det naturliga m\u00e4nskliga hj\u00e4rtat. Realheart<\/em><\/span>\u00ae<\/span><\/span><\/span><\/em> TAH\u00a0inf\u00f6rlivar ett fyrkammarsystem (tv\u00e5 f\u00f6rmak, tv\u00e5 kamrar) vilket ger m\u00f6jlighet att generera ett fysiologiskt anpassat blodfl\u00f6de som efterliknar kroppens naturliga cirkulation. Ett koncept som \u00e4r unikt i den medicintekniska v\u00e4rlden. <\/em><\/span><\/p>\n<\/div>\n